Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Obesity, overweight not linked to acute respiratory hospitalizations

07 Mar 2018

There appears to be no association between overweight or obesity status and the risk of hospitalization during winter respiratory seasons in both adults and children, a recent study has shown.

The study included individuals ≥2 years of age who had fever and/or acute respiratory symptoms over four winter respiratory symptoms. The primary outcome of hospitalization, along with secondary outcomes such as antibiotic prescription and length of stay, were predicted using multivariable logistic regression.

The cohort included 3,560 patients, of whom 749 were children and 2,811 were adults. The overall prevalence of overweight and obesity were 24.2 percent (21.0 percent children; 25.0 percent adults) and 36.4 percent (23.0 percent children; 40.0 percent adults), respectively.

In children, multivariate logistic regression showed that there was no significant association between overweight (adjusted odds ratio [OR], 0.7; 95 percent CI, 0.4–1.3) or obesity (adjusted OR, 1.2; 0.7–2.0) status and hospital admissions.

The secondary outcomes were also unrelated to weight status. Neither overweight nor obesity increased the likelihood of length of stay >2 days (adjusted OR, 1.5; 0.4–5.1 and adjusted OR, 0.7; 0.3–1.9), antibiotic prescription (adjusted OR, 0.7; 0.5–1.2 and adjusted OR, 0.8; 0.6–1.3) and oxygen requirement (adjusted OR, 0.5; 0.2–1.7 and adjusted OR, 1.3; 0.5–3.3).

The same general trend was observed for adults, except for those with class 3 obesity who were at a significantly higher risk of oxygen requirement (adjusted OR, 1.6; 1.1–2.5).

In contrast, the likelihood of the primary outcome was slightly lower in overweight patients (adjusted OR, 0.8; 0.6–1.0) and those with class 1 (adjusted OR, 0.7; 0.5–1.0) or 2 (adjusted OR, 0.6; 0.4–0.8) obesity.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.